Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03277352 · OUTCOME

Phase 1 and Phase 2 : ORR Based on RECIST v1.1 and mRECIST

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies · Source last updated 2021-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months

What was measured

Defined as the percentage of participants having a CR or PR based on investigator assessment per RECIST v1.1.

Analysis population: The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.

Groups in this outcome

INCAGN01876 + Pembrolizumab + Epacadostat

INCAGN01876 in combination with pembrolizumab and epacadostat

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
INCAGN01876 + Pembrolizumab + Epacadostat10

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
INCAGN01876 + Pembrolizumab + Epacadostat3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Defined as the percentage of participants having a CR or PR based on investigator assessment per RECIST v1.1.
groups
  1. description
    INCAGN01876 in combination with pembrolizumab and epacadostat
    id
    OG000
    title
    INCAGN01876 + Pembrolizumab + Epacadostat
param Type
COUNT_OF_PARTICIPANTS
population Description
The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.
reporting Status
POSTED
time Frame
Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months
title
Phase 1 and Phase 2 : ORR Based on RECIST v1.1 and mRECIST
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice